StockData
REVBNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as REVBW

REVELATION BIOSCIENCES, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$3.29+2.80 (+577.76%)

Close on Oct 19, 2026

Market cap
$12.58M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 5, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 6, 2026During market hours–$-0.87–
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026During market hours–$-2.71–
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026During market hours–$-1.65–
Q3 FY2025
Ended Sep 30, 2025
Nov 6, 2025During market hours–$-1.77–
Q2 FY2025
Ended Jun 30, 2025
Aug 8, 2025Before market open–$-7.01–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025During market hours–$-2.11–
Q4 FY2024
Ended Dec 31, 2024
Mar 6, 2025During market hours–$-4.98–
Q3 FY2024
Ended Sep 30, 2024
Nov 8, 2024During market hours–$-0.84–
Q2 FY2024
Ended Jun 30, 2024
Aug 9, 2024During market hours–$-5.13–
Q1 FY2024
Ended Mar 31, 2024
May 10, 2024During market hours–$-2.46–
Q4 FY2023
Ended Dec 31, 2023
Mar 22, 2024During market hours–$-8.33–

Press releases

Announcements Revelation Biosciences filed with the SEC